Ben Goldacre's Blog

Evidence to House of Commons Sci Tech Select Committee on Research Integrity

Sorry not to be in regular blogging mode at the moment. Here’s a video of our evidence session to parliament, where they are running an inquiry into research integrity. I think clinical trials are the best possible way to approach this issue. Lots of things in “research integrity” are hard to capture in hard logical […]

How do the world’s biggest drug companies compare, in their transparency commitments?

Here’s a paper, and associated website, that we launch today: we have assessed, and then ranked, all the biggest drug companies in the world, to compare their public commitments on trials transparency. Regular readers will be familiar with this ongoing battle. In medicine we use the results of clinical trials to make informed treatments about […]

Meaningful Transparency Commitments: the WHO Joint Statement from Trial Funders

By now I hope you all know about the ongoing global scandal of clinical trial results being left unpublished, and of course our AllTrials campaign. Doctors, researchers, and patients cannot make truly informed choices about which treatments work best if they don’t have access to all the trial results. Earlier this year, I helped out […]

How many epidemiologists does it take to change a lightbulb?

Robin Ince just asked if I know any epidemiologist lightbulb jokes. I wrote this for him. How many epidemiologists does it take to change a lightbulb? We’ve found 12,000 switches hidden around this house. Some of them turn this lightbulb on, some of them don’t; some of them only work sometimes; and some of them […]

“Transparency, Beyond Publication Bias”. A video of my super-speedy talk at IJE.

People often talk about “trials transparency” as if this means “all trials must be published in an academic journal”. In reality, true transparency goes much further than this. We need Clinical Study Reports, and individual patient data, of course. But we also need the consent forms, so we can see what patients were told. We need […]

You should totally watch this entire day of the IJE conference

Today marks the end of an era. The International Journal of Epidemiology used to be a typical hotchpotch of isolated papers on worthy subjects. Occasionally, some were interesting, or related to your field. Under Shah Ebrahim and George Davey-Smith it became like nothing else: an epidemiology journal you’d happily subscribe to with your own money, and read in […]

An audio interview with The Conversation, on smashing the walls of the Ivory Tower

The Conversation is a great media outlet, because it’s run by academic nerds, but made for everyone. I had a nice time chatting with them last week: we discussed transparency, data sharing, statins, research integrity, risk communication, culture shift, academic activism, and why we should kick through the walls of the ivory tower. Caution: contains nerds! theconversation.com/speaking-with-bad...

Sarepta, eteplirsen: anecdote, data, surrogate outcomes, and the FDA

The Duchenne’s treatment made by Sarepta (eteplirsen) has been in the news this week, as a troubling example of the FDA lowering its bar for approval of new medicines. The FDA expert advisory panel decided not to approve this treatment, because the evidence for any benefit is weak; but there was extensive lobbying from well-organised patients and, eventually, the FDA overturned the opinion of its own […]

Sarepta: anecdote, data, surrogate outcomes, and the FDA

The Duchenne’s treatment Sarepta (eteplirsen) has been in the news this week, as a troubling example of the FDA lowering its bar for approval of new medicines. The FDA expert advisory panel decided not to approve this treatment, because the evidence for any benefit is weak; but there was extensive lobbying from well-organised patients and, eventually, the FDA overturned the opinion of its own panel. There […]

The Cancer Drugs Fund is producing dangerous, bad data: randomise everyone, everywhere!

There are recurring howls in my work. One of them is this: in general, if you don’t know which intervention works best, then you should randomise everyone, everywhere. This is for good reason: uncertainty costs lives, through sub-optimal treatment. Wherever randomised trials are the right approach, you should embed them in routine clinical care. This is an argument I’ve made, with colleagues, in […]